Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Genetic Disorders

The Expanding Market of Complement Inhibitors

The development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregul...

Dec 18, 2023

Pharma News for Merck, Ipsen, bluebird bio
Merck and Moderna Initiate Study to Evaluate V940; FDA Approves Vertex and CRISPR Therapeutics’ CASGEVY for SCD; Novartis Updated on its Investigational Iptacopan Phase III Study; FDA Grants Priority Review for New Drug Application for Elafibranor; FDA Approves bluebird bio’s LYFGENIA for Patients SCD; FDA Fast Track Designation for DMD Gene Therapy

Merck and Moderna Initiate INTerpath-002, a Phase III Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC Merck (also known as MSD outside the United States and Canada) and Moderna, Inc. have commenced the INTerpath-002 trial—a crucial Phase ...

Find More
Pharma News for AskBio, Almirall, Bayer, Pfizer
Key Updates on Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type; European Commission Approves EBGLYSS; Bayer Stopped OCEANIC-AF Study; Pfizer and Astellas’ XTANDI Approved by FDA; FDA Orphan Drug Designation to Epic Bio’s EPI-321; FDA Fast Track Designation to Chemomab’s CM-101 for PSC

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial ...

Find More
niemann-pick-disease-type-c-treatment
Emerging Therapies for Niemann-Pick Disease Type C Treatment: The Road to Progress

Niemann-Pick disease type C (NPC) is a rare genetic disorder caused by mutations in cholesterol trafficking proteins. There are two main types, with Type C1 being the most prevalent, accounting for around 95% of cases. While specific epidemiological data on NPC is limited, estimates suggest a prevalence of approxim...

Find More

More Views & Analysis

Molecular Modeling Market Analysis
Revolutionizing Drug Discovery and Beyond: The Power of Molecular Modeling

Molecular modeling, a revolutionary branch of science that seeks to understand and manipulate the intricate world of molecules at the atomic and molecular levels, has seen a remarkable transformation in recent years, owing to the growth in technology. The union of computational science, chemistry, and biology has g...

Find More

aav-gene-therapies-for-hemophilia-b-treatment
AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure

Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around 3 in 100 individuals with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The...

Find More

primary-hyperoxaluria-treatment
Can Novo’s Rivfloza Outperform Its Rival Alnylam’s Oxlumo in Primary Hyperoxaluria Treatment Space?

In recent years, Novo Nordisk has been actively addressing the challenges arising from the launch of its highly popular obesity therapy, Wegovy. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza, a trea...

Find More

netherton-syndrome-treatment
Netherton Syndrome: Unraveling the Uncertainties of a Rare Genetic Skin Disorder

Quick Facts about Netherton Syndrome Netherton syndrome, a less common form of ichthyosis, is a monogenic cutaneous condition characterized by congenital scaly erythroderma, evolving into typical erythematous patches with peripheral scaling, hair shaft abnormalities, and atopic manifestation. Netherton syndr...

Find More

orchards-otl-200-for-metachromatic-leukodystrophy-treatment
Orchard’s OTL-200 to Enter US Metachromatic Leukodystrophy Treatment Space After EU

Orchard Therapeutics’ Biologics License Application for OTL-200, a gene therapy under investigation for metachromatic leukodystrophy treatment, has been accepted by the FDA. This rare disease treatment received approval in Europe back in 2020. Notably, the FDA has granted Orchard’s application Priority Review statu...

Find More

huntingtons-disease-treatment
A Turning Point: INGREZZA’s Impact on Huntington’s Disease Treatment and the Rise of Novel Therapies

Huntington’s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about 30,000 people in the United States have Huntington’s disease, and another 200,000 are at risk of developing the condition. As per DelveInsight analy...

Find More

RNAi is a fundamental gene-silencing pathway in eukaryotic cells, where long pieces of double-strand.....

Find More

Pyelonephritis (Kidney infection) is an infection of the kidney, which is a consequence of urinary t.....

Find More

Cachexia is a complicated metabolic syndrome related to underlying illness and characterized by musc.....

Find More

The EU market contains more than 55 biosimilars for around 15 oncology, autoimmune, diabetes, and fe.....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there e.....

Find More